Avedro Announces Schedule of Events at the American Academy of Ophthalmology Annual Meeting
October 09 2019 - 4:30PM
Avedro, Inc. (Nasdaq: AVDR) (Avedro) today announced its schedule
of scientific and educational programs focused on corneal
cross-linking and keratoconus during AAO 2019, the American Academy
of Ophthalmology’s (AAO) 123rd annual meeting that is being held
October 11-15 in San Francisco, CA.
Avedro’s presentations and educational events underscore the
clinical community’s growing interest in the diagnosis and
treatment of keratoconus. Keratoconus is a debilitating eye disease
that, if left untreated, can lead to loss of vision and even
blindness and is the leading cause of corneal transplant
(penetrating keratoplasty) in the United States1.
“Avedro’s corneal cross-linking treatment is becoming
well-established as the only approved therapeutic treatment of
progressive keratoconus. As awareness around the disease and our
treatment has accelerated, the ophthalmic community is more engaged
than ever in learning about best practices,” said Reza Zadno, PhD,
President and Chief Executive Officer (CEO) of Avedro. “Our
programs at AAO 2019 are designed to educate clinicians on
diagnosis and treatment techniques, as well as coding and
reimbursement processes, and will help to further improve the
quality of patient care while expanding patient access to Avedro’s
FDA-approved sight-preserving therapy. We also look forward to
discussing exciting new ways in which cross-linking may be applied
in the future.”
Avedro-sponsored programs are scheduled as follows:
Saturday, October 12
- 10:00-10:10 AM – Leveraging Social Media to Expand
Keratoconus Awareness. Michael Greenwood, MD. Avedro booth
#5415.
- 10:15-10:35 AM – Optimizing the Care of a Keratoconus
Patient. Brandon Ayres, MD & Clark Chang, OD. Avedro
booth #5415.
- 11:00-11:30 AM – CXL Visionary
Series. John Berdahl, MD. Avedro booth #5415.
- 3:15-3:35 PM – CXL Clinical Pearls: Maximizing Workflow
& Efficiency. Michael Raizman, MD & Edward Manche,
MD Avedro booth #5415.
- 5:30-7:30 PM – EVENING SYMPOSIUM: Cross-Linking and
Intracorneal Ring Segment: What You Need to Know. John
Berdahl, MD, Richard Lindstrom, MD, Neda Shamie, MD, William Wiley,
MD, and Raj Rajpal, MD as moderator. Reception and program at the W
Hotel, 181 3rd Street, San Francisco, Social Terrace on 4th
floor.
Sunday, October 13
- 10:00-10:20 AM – Expanding KC Education for Referring
Physicians. Ken Beckman, MD & Jack Parker, MD; Audrey
Talley-Rostov, MD to moderate. Avedro booth #5415.
- 10:25-10:45 AM – How to Talk to Your Keratoconus
Patient & Their Families. Kathryn Hatch, MD, &
Erin Stahl, MD; J. Bradley Randleman, MD to moderate. Avedro booth
#5415.
- 11:00-11:30 AM – CXL Visionary
Series. Vance Thompson, MD. Avedro booth #5415
About Avedro, Inc.Avedro is a leading hybrid ophthalmic
pharmaceutical and medical technology company focused on treating
corneal disease and disorders and improving vision to reduce
dependency on eyeglasses or contact lenses. Avedro’s
proprietary bio-activated pharmaceuticals strengthen, stabilize,
and reshape the cornea to treat corneal ectatic disorders and
correct refractive conditions. Avedro’s suite of single-use
drug formulations are applied to the cornea and bio-activated to
induce a reaction called corneal collagen cross-linking.
Use of Forward-Looking StatementsThis press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to, statements about the rate of adoption and
awareness of Avedro’s corneal cross-linking treatment and future
opportunities for cross-linking. Words such as “anticipates,”
“believes,” “expects,” “intends,” “projects,” “anticipates,” and
“future” or similar expressions are intended to identify
forward-looking statements. Any forward-looking statements are
based on management’s current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. For a
discussion of risks and uncertainties and other important factors,
any of which could cause Avedro’s actual results to differ from
those contained in the forward-looking statements, see the section
titled “Risk Factors” in Avedro’s filings with the SEC,
including each of Avedro’s most recently filed Annual Report on
Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K and other filings with the SEC, which are
available on the SEC’s website at www.sec.gov.
INDICATIONS
Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran
ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate
ophthalmic solution) are indicated for use with the KXL System in
corneal collagen cross-linking for the treatment of progressive
keratoconus and corneal ectasia following refractive surgery.
Corneal collagen cross-linking should not be performed on
pregnant women.
IMPORTANT SAFETY INFORMATION
Ulcerative keratitis can occur. Patients should be monitored for
resolution of epithelial defects.
The most common ocular adverse reaction was corneal opacity
(haze). Other ocular side effects include punctate keratitis,
corneal striae, dry eye, corneal epithelium defect, eye pain, light
sensitivity, reduced visual acuity, and blurred vision.
These are not all of the side effects of the corneal collagen
cross-linking treatment. For more information, go to
www.livingwithkeratoconus.com/ to obtain the FDA-approved product
labeling.
You are encouraged to report all side effects to the FDA. Visit
www.fda.gov/medwatch, or call 1-800-FDA-1088.
References:
- Borderie VM, Boelle PY, Touzeau O, et al. Predicted long-term
Outcome of corneal transplantation. Ophthalmology 2009;2354-2360
Eye Bank Association of America Statistical Report, 2016
Avedro
Contact:David Iannetta (781) 768-3400info@avedro.com |
Investor Contact:Brian Johnston or Lynn
Lewis (415) 937-5400investors@avedro.com |
Avedro (NASDAQ:AVDR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Avedro (NASDAQ:AVDR)
Historical Stock Chart
From Oct 2023 to Oct 2024